|
A serotonin-dopamine releasing agent (SDRA) is a type of drug which induces the release of serotonin and dopamine in the body and/or brain. A number of tryptamine derivatives have been found to act as SDRAs. One such agent is 5-chloro-αMT (PAL-542), which has been reported as having about 64-fold selectivity for dopamine release over norepinephrine release and about 3-fold selectivity for serotonin release over dopamine release, making it a highly selective and well-balanced SDRA. Another agent is 5-fluoro-αET (PAL-545), which has about 35-fold selectivity for dopamine release over norepinephrine release and about 4-fold selectivity for serotonin release over dopamine release.〔 Though selective for inducing the release of serotonin and dopamine over norepinephrine, these agents are not selective monoamine releasers; they have all also been found to be potent agonists of the 5-HT2A receptor, and may act as agonists of other serotonin receptors as well.〔 UWA-101 is a reuptake inhibitor of serotonin and dopamine, but may also have efficacy as a releasing agent of these neurotransmitters. ==See also== * Monoamine releasing agent * Serotonin-dopamine reuptake inhibitor 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Serotonin-dopamine releasing agent」の詳細全文を読む スポンサード リンク
|